Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination dietary supplement** composed of the carotenoids **lutein** and **zeaxanthin** and the omega-3 fatty acid **docosahexaenoic acid (DHA)**. Lutein and zeaxanthin are xanthophyll carotenoids that accumulate in the retina, especially the macula, where they function as **antioxidants** and **blue light filters** that protect photoreceptor cells from light-induced oxidative stress and damage. Docosahexaenoic acid is an omega-3 fatty acid that is a major structural lipid in the retina, especially in photoreceptor outer segments, and contributes to retinal health through anti-inflammatory mechanisms and membrane stabilization. The combination is designed to support and preserve visual function, especially in conditions of increased oxidative stress or high exposure to blue light (e.g., from digital device use), and to potentially reduce risk or progression of age-related macular degeneration (AMD). Multiple randomized controlled trials have evaluated the effects of this combination or closely related formulas on macular pigment optical density (MPOD), visual performance, and progression of retinal diseases[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lutein + zeaxanthin + docosahexaenoic acid.